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Ursodeoxycholic acid versus placebo in women with 
intrahepatic cholestasis of pregnancy (PITCHES): 
a randomised controlled trial
Lucy C Chappell, Jennifer L Bell, Anne Smith, Louise Linsell, Edmund Juszczak, Peter H Dixon, Jenny Chambers, Rachael Hunter, Jon Dorling, 
Catherine Williamson*, Jim G Thornton*, for the PITCHES study group†
Summary
Background Intrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid 
concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission. 
Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base. We aimed to evaluate whether 
ursodeoxycholic acid reduces adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy.
Methods We did a double-blind, multicentre, randomised placebo-controlled trial at 33 hospital maternity units in 
England and Wales. We recruited women with intrahepatic cholestasis of pregnancy, who were aged 18 years or older 
and with a gestational age between 20 weeks and 40 weeks and 6 days, with a singleton or twin pregnancy and no 
known lethal fetal anomaly. Participants were randomly assigned 1:1 to ursodeoxycholic acid or placebo, given as two 
oral tablets a day at an equivalent dose of 500 mg twice a day. The dose could be increased or decreased at the 
clinician’s discretion, to a maximum of four tablets and a minimum of one tablet a day. We recommended that 
treatment should be continued from enrolment until the infant’s birth. The primary outcome was a composite of 
perinatal death (in-utero fetal death after randomisation or known neonatal death up to 7 days after birth), preterm 
delivery (<37 weeks’ gestation), or neonatal unit admission for at least 4 h (from birth until hospital discharge). Each 
infant was counted once within this composite. All analyses were done according to the intention-to-treat principle. 
The trial was prospectively registered with the ISRCTN registry, number 91918806.
Findings Between Dec 23, 2015, and Aug 7, 2018, 605 women were enrolled and randomly allocated to receive 
ursodeoxycholic acid (n=305) or placebo (n=300). The primary outcome analysis included 304 women and 322 infants 
in the ursodeoxycholic acid group, and 300 women and 318 infants in the placebo group (consent to use data was 
withdrawn for 1 woman and 2 infants). The primary composite outcome occurred in 74 (23%) of 322 infants in the 
ursodeoxycholic acid group and 85 (27%) of 318 infants in the placebo group (adjusted risk ratio 0·85 [95% CI 
0·62–1·15]). Two serious adverse events were reported in the ursodeoxycholic acid group and six serious adverse 
events were reported in the placebo group; no serious adverse events were regarded as being related to treatment.
Interpretation Treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes in women with 
intrahepatic cholestasis of pregnancy. Therefore, its routine use for this condition should be reconsidered.
Funding National Institute for Health Research Efficacy and Mechanism Evaluation Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Intrahepatic cholestasis of pregnancy, also called 
obstetric cholestasis, is the most common liver disorder 
specific to pregnancy. The disease is characterised 
by maternal pruritus and increased serum bile acid 
concentrations, with maternal symptoms and abnormal 
biochemical test results typically resolving post partum. 
A systematic review and individual patient data meta-
analysis1 from 2019 showed that intrahepatic cholestasis 
of pregnancy is associated with increased rates of 
spontaneous and iatrogenic preterm birth, meconium-
stained amniotic fluid, and neonatal unit admission. 
In addition, the risk of stillbirth was found to be 
increased only for women with peak serum bile acid 
concentrations of 100 μmol/L or higher,1 in contrast to 
the previously held belief that the risk of stillbirth was 
increased for all women with intrahepatic cholestasis of 
pregnancy.2
Ursodeoxycholic acid, which is used outside of 
pregnancy to treat primary biliary cholangitis and other 
hepatobiliary disorders, has been used to treat intrahepatic 
cholestasis of pregnancy.3 Ursodeoxycholic acid is a 
naturally occurring bile acid that is present in small 
amounts in humans. It has several actions that result in 
the improvement of cholestasis, including increasing 
biliary bile acid excretion through upregulation of 
hepatic metabolising enzymes and bile acid transporters, 
stimulation of impaired hepatocellular secretion by 
Lancet 2019; 394: 849–60
Published Online 
August 1, 2019 
http://dx.doi.org/10.1016/
S0140-6736(19)31270-X
See Comment page 810
*Joint senior authors
†A full list of collaborators is 
provided in the appendix
Department of Women and 
Children’s Health, School of Life 
Course Sciences, King’s College 
London, London, UK 
(Prof L C Chappell PhD, 
P H Dixon PhD, 
Prof C Williamson MD); National 
Perinatal Epidemiology Unit 
Clinical Trials Unit, Nuffield 
Department of Population 
Health, University of Oxford, 
Oxford, UK (J L Bell MSc, 
A Smith, L Linsell DPhil, 
E Juszczak MSc); ICP Support, 
Sutton Coldfield, UK 
(J Chambers BPhil); Research 
Department of Primary Care 
and Population Health, 
University College London, 
London, UK (R Hunter MSc); 
Division of Neonatal-Perinatal 
Medicine, IWK Health Centre, 
Halifax, NS, Canada 
(Prof J Dorling MD); and 
Division of Child Health, 
Obstetrics and Gynaecology, 
University of Nottingham, 
Nottingham, UK 
(Prof J G Thornton MD)
Correspondence to: 
Prof Lucy Chappell, Department 
of Women and Children’s Health, 
School of Life Course Sciences, 
King’s College London, 
London SE1 7EH, UK 
lucy.chappell@kcl.ac.uk
See Online for appendix
Articles
850 www.thelancet.com   Vol 394   September 7, 2019
post-transcriptional mechanisms, stabilisation of the 
plasma membrane and protection of cholangiocytes of 
the biliary epithelium against cytotoxicity of bile 
acids, and hepatocyte protection against bile acid-induced 
apoptosis.4,5 Urso de oxycholic acid is recommended in 
six national guidelines for management of intrahepatic 
cholestasis of pregnancy,6 principally for the improvement 
of maternal symptoms and biochemical test results. 
Surveys of practice have found that 97% of obstetricians 
in the UK use ursodeoxycholic acid for treating intra-
hepatic cholestasis of pregnancy.7
Despite widespread recommendations of ursodeoxy-
cholic acid in the treatment of intrahepatic cholestasis 
of pregnancy, the evidence base for its use is scant. 
Two meta-analyses had been done shortly before the 
inception of our trial.8,9 One meta-analysis found that 
ursodeoxycholic acid was effective in reducing pruritus 
and improving liver test results in women with intra-
hepatic cholestasis of pregnancy, and might improve fetal 
outcomes; however, the largest randomised controlled 
trial included had only 84 participants.8 A subsequent 
Cochrane systematic review of the effectiveness of ursode-
oxycholic acid for intrahepatic cholestasis of pregnancy 
concluded that it might ameliorate pruritus by a small 
amount, but that definitive evidence for improvement in 
perinatal outcomes was absent and large trials of 
ursodeoxycholic acid were needed to determine fetal 
benefits or risks.9 The Cochrane review found that many 
of the trials were at a moderate-to-high risk of bias, and 
the largest trial included only 111 women.10
We did a randomised placebo-controlled trial to 
evaluate whether ursodeoxycholic acid reduces adverse 
perinatal outcomes in women with intrahepatic 
cholestasis of pregnancy, and to investigate the effect of 
ursodeoxycholic acid on other short-term maternal and 
infant outcomes, and on the use of health-care resources.
Methods
Study design
We did a parallel-group, double-blind, multicentre, 
randomised placebo-controlled trial with individual 
randomisation to ursodeoxycholic acid or placebo using a 
1:1 allocation ratio. The trial was done at 33 hospital 
maternity units in England and Wales. The trial was 
approved by the East of England—Essex Research Ethics 
Committee (15/EE/0010). The study protocol has been 
published previously.11 No substantial changes were 
made to the study design or methods after commence-
ment of the trial.
Participants
Women were eligible if the attending clinician considered 
that they had a diagnosis of intrahepatic cholestasis of 
pregnancy (defined as maternal pruritus with an increase 
in serum bile acid concentration above the upper limit of 
normal at randomly timed assessment, as measured in 
the local laboratory),12 and they were between 20 weeks 
and 40 weeks and 6 days of pregnancy on the day of 
randomisation, with a singleton or twin pregnancy, no 
known lethal fetal anomaly, aged 18 years or older, and 
able to give written informed consent. The diagnostic 
criteria were based on the UK standard-of-care guideline 
from the Royal College of Obstetricians and 
Gynaecologists, which defines intrahepatic cholestasis of 
pregnancy as “when otherwise unexplained pruritus 
occurs in pregnancy and abnormal liver function tests 
and/or raised bile acids occur in the pregnant woman and 
both resolve after delivery”.12 However, we required the 
more stringent criterion that all women had raised bile 
acid concentrations. In accordance with the UK guideline, 
all participating units used randomly timed bile acid 
concentrations for diagnostic and management purposes. 
Because we were recruiting prospectively to the trial, we 
Research in context
Evidence before this study
The Cochrane systematic review on this topic, updated on 
Feb 20, 2013, concluded that “fewer instances of fetal 
distress/asphyxial events were seen in the ursodeoxycholic acid 
groups when compared with placebo but the difference was not 
statistically significant” and larger trials were needed.
Added value of this study
This trial is five times larger than the largest previous trial and 
nearly three times larger than all previous trials combined. 
Women were managed in a high-income health-care setting, 
with free access to care and regular surveillance (including 
repeated bile acid measurements), such that the trial is likely to 
represent current management of this condition.
Implications of all the available evidence
An updated systematic review and meta-analysis, including 
this trial, with the search conducted by the Cochrane Pregnancy 
and Childbirth Group (updated Dec 5, 2018), found that 
ursodeoxycholic acid does not reduce the incidence of stillbirth 
(incidence of one in the ursodeoxycholic acid group vs four in 
the placebo group, relative risk [RR] 0·39 [95% CI 0·08–1·93]; 
five trials, 891 participants; quality of evidence low) or 
spontaneous preterm birth before 37 weeks’ gestation (RR 0·78 
[95% CI 0·49–1·23]; three trials, 749 participants; quality of 
evidence high). However, ursodeoxycholic acid might reduce 
total (spontaneous and iatrogenic) preterm birth (RR 0·68 
[95% CI 0·52–0·89]; three trials, 819 participants, including one 
low quality). Ursodeoxycholic acid does not reduce neonatal 
unit admission (RR 0·77 [95% CI 0·55–1·08]; two trials, 
764 participants; quality of evidence high). Ursodeoxycholic 
acid does not seem to have any significant clinical benefit when 
used routinely for treatment of women with intrahepatic 
cholestasis of pregnancy.
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could not confirm post-partum resolution at the time of 
enrolment. Women were not included in the trial if a 
decision had already been made for delivery within the 
next 48 h, if they had any known allergy to any component 
of the ursodeoxycholic acid or placebo tablets, or if they 
had a triplet or higher-order multiple pregnancy. 17 of the 
33 maternity units used a threshold of 14 µmol/L as the 
upper limit of normal, whereas the remaining units used 
thresholds between 10 µmol/L and 13 µmol/L, according 
to local laboratory reference ranges. Research teams at 
each site approached women to confirm eligibility and 
provided verbal and written information. A trained 
clinician obtained written informed consent.
Randomisation and masking
Participants were randomly allocated to receive 
ursodeoxycholic acid or placebo. Randomisation was 
done using a probabilistic minimisation algorithm to 
ensure approximate balance within the following groups: 
study centre, gestational age at randomisation (<34 weeks’ 
gestation, 34 to <37 weeks’ gestation, ≥37 weeks’ 
gestation), singleton versus twin pregnancy, and highest 
serum bile acid concentration before randomisation 
(<40 µmol/L, ≥40 µmol/L). The minimisation algorithm 
was implemented by a MedSciNet database programmer, 
with balance and predictability checked by an independent 
National Perinatal Epidemiology Unit Clinical Trials Unit 
statistician during the trial. Randomisation was managed 
via a secure web-based randomisation program.
Ursodeoxycholic acid tablets and placebo tablets were 
manufactured by Dr Falk Pharma (Freiburg im Breisgau, 
Germany). The two types of tablet appeared identical in 
size, shape, and colour. Packs of ursodeoxycholic acid or 
placebo in identical packaging were produced by the 
central manufacturing unit at Guy’s and St Thomas’ 
Hospital (London, UK) and shipped to site pharmacies. 
The tablets were packaged for oral administration and 
did not require any special storage conditions. Packs 
were labelled with unique pack identifiers according 
to a randomly generated sequence known only to 
the manufacturing unit and the trial programmers. A 
research team member entered baseline data on a web-
based database at study enrolment and then allocated 
a pack number using the web-based randomisation 
program, which corresponded to a pack for dispensing by 
that site’s pharmacy. If more packs were required, the 
randomisation program was used to allocate further 
packs containing the same allocation. Women who were 
taking ursodeoxycholic acid at enrolment agreed to stop 
the medication at randomisation.
Trial participants, clinical care providers, outcome 
assessors, and data analysts were all masked to allocation.
Procedures
Each film-coated ursodeoxycholic acid tablet contained 
500 mg ursodeoxycholic acid (active ingredient) and the 
following inactive ingredients: magnesium stearate, 
polysorbate 80, povidone K 25, microcrystalline cellulose, 
colloidal anhydrous silica, crospovidone, and talc. The 
placebo tablet contained identical inactive ingredients.
We recommended that women were started on a dose 
of two oral tablets a day (equivalent to 500 mg 
ursodeoxycholic acid twice a day in the ursodeoxycholic 
acid group). The dose was increased by a health-care 
professional in increments of one tablet a day every 
3–14 days if there was no biochemical or symptomatic 
improvement, to a maximum of four tablets per day 
(equivalent to 2000 mg ursodeoxycholic acid per day). 
The dose could be reduced to one tablet a day (equivalent 
to 500 mg ursodeoxycholic acid a day) at a clinician’s 
discretion (eg, if a woman’s bodyweight was <50 kg or if 
gastrointestinal side-effects occurred). We advised that 
doses should be spread evenly throughout the day, but 
that no specific instructions to take with or without 
food needed to be given. We recommended that 
treatment should be continued from enrolment until 
the infant’s birth.
Clinical teams reviewed participants at routine-care 
clinic visits until delivery. Antenatal care, particularly the 
timing and mode of delivery, was at the discretion 
of the responsible clinician. Outcomes were recorded on 
the web-based trial database through case-note review 
by trained researchers after discharge of the woman 
and infant.
Outcomes
The primary outcome was prespecified as a composite of 
perinatal death (defined as in-utero fetal death after 
randomisation or known neonatal death up to 7 days 
after birth), preterm delivery (<37 weeks’ gestation), or 
neonatal unit admission for at least 4 h (from birth until 
hospital discharge). Each infant was counted once within 
this composite.
Secondary maternal outcomes, measured at clinical 
visits between randomisation and delivery, were maternal 
serum concentrations of bile acids, alanine transaminase 
(or aspartate transaminase), total bilirubin, and γ-glutamyl 
transferase, and maternal itch score (measured as the 
worst episode of itch over the past 24 h in mm on a 
100-mm visual analogue scale). Additional secondary 
maternal outcomes, assessed on case-note review after 
maternal discharge, were gestational diabetes, mode of 
onset of labour, and estimated blood loss after delivery.
Secondary perinatal outcomes, assessed on case-note 
review after infant discharge, included the components 
of the primary outcome, mode of delivery, birthweight, 
birthweight percentile, gestational age at delivery, 
presence of meconium, Apgar score at 5 min, umbilical 
arterial pH at birth, and number of nights in the neonatal 
unit. All other secondary outcomes were descriptive only.
Health-resource use post-enrolment was collected at 
case-note review after maternal and infant discharge. 
Maternal use was assessed as: total number of nights in 
hospital (antenatal, intrapartum, and postnatal) together 
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with the level of care, including adult intensive care unit 
(ICU); mode of delivery; and cost of ursodeoxycholic acid 
(in intervention group). Infant use was assessed as: total 
number of nights in the neonatal unit, together with level 
of care (eg, ICU). Information on outpatient appointments 
was not collected, because the same outpatient clinical 
follow-up before the birth was required for both groups.
Research teams undertook standard assessments of 
safety, with reporting of adverse events and serious 
adverse events following usual governance procedures 
for a clinical trial of an investigational medicinal product 
overseen by the UK Medicines and Healthcare Regulatory 
Agency. 
Statistical analysis
The sample size was informed by the Cochrane meta-
analysis,9 in which the event rate for the primary outcome 
for the infants of untreated women was estimated to 
be 40%. We calculated that 550 infants of women with 
intrahepatic cholestasis of pregnancy (275 per group) 
were required for a 90% chance of detecting (significant 
at the two-sided 5% level) a reduction in the primary 
outcome measure from 40% in the control group to 27% 
in the treated group, corresponding to an absolute risk 
reduction of 13% and a risk ratio (RR) of 0·675. This 
estimate was conservative compared with the effect sizes 
in the Cochrane meta-analysis9 for the three individual 
endpoints (RR 0·31 for perinatal death, 0·46 for preterm 
delivery, and 0·48 for neonatal unit admission). We 
planned to recruit 580 women in total, to allow for the 
possibility of 5% of infants being lost to follow-up. 
During the recruitment phase, we amended the protocol 
to permit continued recruitment of additional 
participants, to allow for women who discontinued the 
intervention or withdrew from the trial. Interim analyses 
were done only for presentation to the Data Monitoring 
Committee, to be reviewed when the committee met at 
least annually.
The analysis and presentation of results follows the 
recommendations of the CONSORT group. Full details 
of the statistical analysis are in the appendix (pp 3–25) 
and were prespecified.12 Statistical analysis was done in 
Stata version 15. Unmasked data were made available for 
analysis only after a full database lock (after all data entry 
had been completed and queries resolved) or on request 
by the Data Monitoring Committee. All analyses followed 
the intention-to-treat principle: all randomly allocated 
women (and infants) were analysed according to the 
group they were allocated to, irrespective of the treatment 
they received, if any.
Demographic and clinical data were presented as n (%) 
for categorical variables, mean (SD) for normally dis-
tributed continuous variables, and median (IQR) or 
median (range) for other continuous variables. All com-
parative analyses were done adjusting for minimisation 
factors at randomisation,13 with centre as a random effect 
and the other variables fitted as fixed effects. In addition, 
Figure 1: Trial profile
*Reasons are not mutually exclusive. †322 of 323 infants born to women allocated to ursodeoxycholic acid; 
one infant was excluded because the mother withdrew consent for use of data and further data collection. ‡318 of 
319 infants born to women allocated to placebo; one infant was excluded because the mother withdrew consent 
for further data collection.
305 allocated to ursodeoxycholic acid
300 received ursodeoxycholic acid
5 received no treatment
605 randomly allocated
1418 eligible
813 declined to participate
108 did not want to be randomly allocated
112 did not want ursodeoxycholic acid
287 did want ursodeoxycholic acid
126 not interested in research
174 other
6 reason missing
1319 ineligible
2737 women assessed for eligibility
304 women analysed for primary outcome
322 infants† analysed for primary outcome
24 discontinued intervention*
10 clinician decision
16 participant decision
1 withdrew from trial
1 withdrew consent for further data 
collection and consent to use data
300 allocated to placebo
296 received placebo
4 received no treatment
300 women analysed for primary outcome
318 infants‡ analysed for primary outcome
29 discontinued intervention*
10 clinician decision
22 participant decision
1 withdrew from trial
1 withdrew consent for further data 
collection
Ursodeoxycholic acid 
(n=304)
Placebo 
(n=300)
Age, years 30·5 (5·6) 30·8 (5·3)
Ethnic group
White 247 (81%) 246 (82%)
Black 10 (3%) 7 (2%)
Asian 34 (11%) 40 (13%)
Other 11 (4%) 7 (2%)
Not known 2 (1%) 0
Body-mass index at start of pregnancy (kg/m²), mean (SD) 27·4 (6·4) 26·9 (6·1)
Smoked at start of pregnancy 33 (11%) 44 (15%)
Indices of Multiple Deprivation score: quintile 5*, n/N (%) 76/289 (26%) 81/286 (28%)
Not defined, n 15 14
Previous pregnancy of ≥24 weeks’ gestation 178 (59%) 193 (64%)
Previous stillbirth 2 (1%) 2 (1%)
(Table 1 continues on next page)
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for perinatal outcomes for which the denominator was 
the number of infants, the correlation among twins was 
accounted for by nesting the mother’s identification 
number as a random effect within centre. Both unadjusted 
and adjusted effect estimates are presented, but the 
primary inference is based on the adjusted estimates.
Binary outcomes were analysed using mixed-effect 
Poisson regression models with robust variance 
estimation and results were presented as adjusted RRs 
with 95% CIs.14 Continuous outcomes were analysed 
using mixed-effect linear regression models and 
presented as adjusted mean differences with 95% CIs. 
Skewed continuous variables were analysed using 
quantile regression with minimisation factors (excluding 
centre) fitted as fixed effects, and results were presented 
as median differences with 95% CIs. Analysis of 
outcomes that were measured repeatedly over time 
(severity of itch and biochemistry measures) used 
repeated measures models, with means or geometric 
means of the post-randomisation observations reported,15 
and the trial groups compared using a mean difference or 
geometric mean ratio, adjusted for the baseline measures 
(such that the summary statistics are adjusted for chance 
imbalances at baseline) and minimisation factors.
Prespecified subgroup analyses were done for the 
primary outcome and its components, bile acid and itch 
outcomes, using a statistical test of interaction. Binary 
outcomes are presented as RRs with 95% CIs on a 
forest plot. Prespecified subgroups were based on the 
criteria selected for minimisation: highest serum bile 
acid concentration before randomisation (<40 μmol/L, 
≥40 μmol/L); gestational age at randomisation 
(<34 weeks’ gestation, ≥34 weeks’ gestation); singleton 
or twin pregnancy.
After discussion of the results of the prespecified 
analysis, and taking into account the findings of a 2019 
meta-analysis,1 the Trial Steering Committee and Data 
Monitoring Committee requested two additional post-
hoc analyses: the number and percentage of women 
with peak bile acid of less than 100 μmol/L or at least 
100 μmol/L before randomisation, with the primary 
outcome and its components stratified by this result; 
and the number and percentage of infants with a 
spontaneous preterm birth or an iatrogenic preterm 
birth, with a subgroup analysis of these infants by the 
minimisation factors specified for the other subgroup 
analyses. A Kaplan-Meier plot from randomisation to 
delivery estimate has been included at the request of 
a reviewer.
Sensitivity analyses were done for the primary 
outcome, itch score, and bile acid concentration between 
randomisation and delivery, excluding women or infants 
of mothers who did not adhere to the intervention 
(<90% medication adherence consistently self-reported).
In the context of a fixed health-care budget it is 
important for health-care payers to have information on 
the potential cost implications of changes in clinical 
practice. Therefore, we decided to collect data on mother 
and infant inpatient care and mode of delivery, which 
were costed using the National Health Service’s national 
schedule of reference costs (appendix p 26).16 The cost of 
ursodeoxycholic acid (derived from the British National 
Formulary17) was included for women who were randomly 
allocated to receive the intervention. Descriptive statistics 
are reported, including mean cost per participant and 
95% CIs constructed using bootstrapping. Comparative 
differences in cost were calculated using linear regression, 
adjusting for gestational age at randomisation, bile acid 
Ursodeoxycholic acid 
(n=304)
Placebo 
(n=300)
(Continued from previous page)
History of intrahepatic cholestasis of pregnancy, n/N (%) 92/175 (53%) 90/190 (47%)
Missing, n 3 3
Pre-pregnancy liver disease 3 (1%) 6 (2%)
Liver ultrasound at randomisation, n/N (%) 79/293 (27%) 78/292 (27%)
Normal, n/N (%) 65/77 (84%) 57/77 (74%)
Gallstones, n/N (%) 9/77 (12%) 12/77 (16%)
Other abnormality, n/N (%) 3/77 (4%) 8/77 (10%)
Missing result, n 2 1
Previous operation for gallstones 20 (7%) 17 (6%)
Pre-pregnancy diabetes 4 (1%) 4 (1%)
Gestational age (weeks), median (IQR)† 34·4 (32·1–35·9) 34·4 (31·5–36·0)
<34 weeks 133 (44%) 131 (44%)
34 to <37 weeks 141 (46%) 141 (47%)
≥37 weeks 30 (10%) 28 (9%)
Twin pregnancy† 18 (6%) 19 (6%)
Gestational diabetes 32 (11%) 25 (8%)
Itch score, mean (SD)‡ 57·1 (25·1) 59·5 (25·1)
Medication for pruritus§, n/N (%) 146/298 (49%) 137/297 (46%)
Antihistamine, n/N (%) 121/298 (41%) 119/297 (40%)
Topical emollient, n/N (%) 102/298 (34%) 101/297 (34%)
Ursodeoxycholic acid, n/N (%) 15/298 (5%) 13/297 (4%)
Missing, n 6 3
Highest baseline serum concentration before randomisation
Bile acid (μmol/L), geometric mean (95% CI)† 28·1 (26·0–30·3) 26·9 (24·9–29·0)
<40 μmol/L 232 (76%) 228 (76%)
≥40 μmol/L 72 (24%) 72 (24%)
Alanine transaminase, N 286 286
Alanine transaminase (U/L), geometric mean (95% CI) 70·0 (61·5–79·6) 59·5 (52·0–68·1)
Aspartate transaminase, N 47 48
Aspartate transaminase (U/L), geometric mean (95% CI) 49·0 (38·4–62·5) 61·6 (46·8–81·0)
γ-glutamyl transferase, N 135 138
γ-glutamyl transferase (U/L), geometric mean (95% CI) 23·3 (20·6–26·4) 21·0 (19·0–23·2)
Bilirubin, N 289 275
Bilirubin (μmol/L), geometric mean (95% CI) 8·5 (7·9–9·1) 8·0 (7·4–8·6)
Data are n (%), unless otherwise indicated; N is equal to the total number of participants in the group, unless otherwise 
indicated; <1% of observations are missing, unless indicated. *Quintile 5 represents the most deprived geographical 
areas; scores are not defined for women from Wales.18 †Minimisation criterion. ‡Measured by self-reported worst 
episode of itch over the past 24 h (mm on visual analogue scale). §Not mutually exclusive (some participants used 
more than one).
Table 1: Maternal baseline characteristics
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concentration, singleton versus twin pregnancy, and 
centre as a random effect. The analysis is from a health-
service payer perspective.
The trial is registered with the ISRCTN registry, 
number 91918806.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Dec 23, 2015, and Aug 7, 2018, 2737 women were 
screened, of whom 1418 were found to be eligible 
(figure 1). We recruited 605 (43%) of 1418 women, 
including 37 women with a twin pregnancy, across 
33 maternity units (appendix p 27). 305 women were 
randomly allocated to ursodeoxycholic acid, with 
304 women and 322 infants included in the primary 
outcome analysis. 300 women were allocated to placebo, 
with 300 women and 318 infants included in the primary 
outcome analysis. Follow-up to maternal and infant 
discharge continued until December, 2018. Because 
we met our recruitment target ahead of schedule, we 
continued recruitment to compensate for the number of 
women who discontinued the intervention or withdrew 
from the trial (with approval of the funder, sponsor, and 
ethics committee), such that our total number of women 
recruited (n=605) included the target sample size (n=550), 
the number who discontinued the intervention (n=53) 
and those who withdrew (n=2). Recruitment ended after 
605 women had been enrolled. Baseline characteristics 
were similar in the two groups (table 1). At enrolment, the 
groups were well balanced on minimisation factors.
Ursodeoxycholic acid 
(n=322)
Placebo (n=318) Adjusted effect estimate (95% CI) p value
Perinatal death, preterm delivery,* or neonatal 
unit admission
74 (23%) 85 (27%) RR 0·85 (0·62 to 1·15) 0·28
In-utero fetal death 1 (<1%) 2 (1%) RR 0·51 (0·04 to 6·25) 0·60
Preterm delivery* 54 (17%) 65 (20%) RR 0·79 (0·57 to 1·10) 0·17
Known neonatal death up to 7 days after birth 0 0 ·· ··
Neonatal unit admission for ≥4 h 45 (14%) 54 (17%) RR 0·81 (0·58 to 1·13) 0·21
Livebirth 321 (>99%) 316 (99%) ·· ··
Gestational age at delivery, weeks 37·6 (37·1–38·1) 37·4 (37·0–38·1) Median difference 0·1 (0·0 to 0·3) 0·065
Birthweight, g 3105 (2775–3390) 3040 (2660–3320) Median difference 94·0 (18·7 to 169·3) 0·014
Birthweight percentile† 59·3 (28·4) 56·3 (27·8) ·· ··
<10th percentile 16 (5%) 18 (6%) RR 0·89 (0·47 to 1·69) 0·73
<3rd percentile 7 (2%) 7 (2%) RR 1·09 (0·38 to 3·12) 0·88
Mode of delivery
Spontaneous vaginal (cephalic) 193 (60%) 182 (57%) RR 1·04 (0·91 to 1·20) 0·56
Vaginal (breech) 1 (<1%) 3 (1%) ·· ··
Assisted vaginal (cephalic) 21 (7%) 35 (11%) ·· ··
Pre-labour caesarean 71 (22%) 62 (19%) ·· ··
Caesarean 36 (11%) 36 (11%) RR 1·00 (0·68 to 1·46) 1·0
Presence of meconium-stained amniotic fluid 34 (11%) 52 (16%) RR 0·65 (0·43 to 0·98) 0·040
Apgar score at 5 min after birth‡ 9·0 (9·0–10·0) 9·0 (9·0–10·0) Median difference 0 (–0·4 to 0·4) 1·0
Apgar score of <7 at 5 min after birth‡, n/N (%) 8/321 (2%) 7/316 (2%) ·· ··
Umbilical cord blood sampling, N 112 102 ·· ··
Umbilical arterial pH 7·2 (0·1) 7·2 (0·1) Mean difference –0·02 (–0·04 to 0·01) 0·18
Nights in the neonatal unit§ 5·5 (3·0–13·0) 6·0 (2·0–16·0) Median difference 0 (–3·2 to 3·2) 1·0
Main diagnosis for first neonatal unit admission
Prematurity, n/N (%) 14/45 (31%) 17/54 (31%) ·· ··
Respiratory disease, n/N (%) 16/45 (36%) 15/54 (28%) ·· ··
Infection suspected or confirmed, n/N (%) 5/45 (11%) 7/54 (13%) ·· ··
Other¶, n/N (%) 10/45 (22%) 15/54 (28%) ·· ··
Data are n (%), median (IQR), or mean (SD), unless otherwise indicated; N is equal to the total number of infants in the group, unless otherwise indicated; <1% of observations 
are missing, unless otherwise indicated. Adjusted effect estimates and p values are shown for primary outcomes, and for secondary outcomes that were prespecified for 
testing in the published protocol. 11 RR=risk ratio. *Delivery at <37 weeks’ gestation. †Calculated using the INTERGROWTH-21st tool.19 ‡Data are for livebirths only. §Data are 
for infants with at least one night in a neonatal unit only. ¶A full list of diagnoses is given in the appendix (p 29).
Table 2: Perinatal outcomes
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The incidence of the primary outcome (perinatal death, 
preterm delivery, or neonatal unit admission for ≥4 h) did 
not differ significantly between the groups: 74 (23%) 
of 322 infants in the ursodeoxycholic acid group versus 
85 (27%) of 318 infants in the placebo group had the 
primary outcome (adjusted RR 0·85 [95% CI 0·62–1·15], 
p=0·28; table 2). The incidence of the primary outcome 
components also did not differ significantly between 
the groups. Three in-utero fetal deaths occurred after 
randomisation: one in the ursodeoxycholic acid group 
and two in the placebo group, with two occurring at 
35 weeks’ gestation and one at 37 weeks’ gestation.
We found no significant difference in median 
gestational age at delivery (table 2); time from 
randomisation to delivery is shown graphically in the 
appendix (p 28). The proportions of infants who were 
delivered by spontaneous vaginal birth or caesarean 
section were similar in the two groups. No significant 
Ursodeoxycholic acid 
(n=304)
Placebo 
(n=300)
Adjusted effect estimate 
(95% CI)
p value
Itch score*, N 241 227 ·· ··
Itch score†, mm 49·5 (12·9) 56·9 (13·3) Mean difference –5·7 (–9·7 to –1·7) 0·0054
Maternal serum bile acid concentration*, N 256 247 ·· ··
Maternal serum bile acid concentration† (μmol/L), 
geometric mean (95% CI)
22·4 (21·4 to 23·5) 18·5 (17·7 to 19·4) Geometric mean ratio 1·18 
(1·02 to 1·36)
0·030
Maternal serum alanine transaminase*, N 242 240 ·· ··
Maternal serum alanine transaminase† (U/L), 
geometric mean (95% CI)
49·5 (43·8 to 55·8) 58·0 (51·0 to 65·9) Geometric mean ratio 0·74 
(0·66 to 0·83)
<0·0001
Gestational diabetes 3 (1%) 9 (3%) RR 0·33 (0·10 to 1·10) 0·071
Additional therapy for cholestasis†, n/N (%) 134/261 (51%) 125/245 (51%) ·· ··
Antihistamine, n/N (%) 102/134 (76%) 105/125 (84%) ·· ··
Topical emollient, n/N (%) 101/134 (75%) 93/125 (74%) ·· ··
Rifampicin, n/N (%) 1/134 (1%) 2/125 (2%) ·· ··
Open-label ursodeoxycholic acid (tablets stopped), 
n/N (%)
17/134 (13%) 21/125 (17%) ·· ··
Delivered before first follow-up visit, n 33 42 ·· ··
Missing, n 10 13 ·· ··
Maximum dose of trial medication
One tablet once a day 4 (1%) 5 (2%) ·· ··
One tablet twice a day 203 (67%) 198 (66%) ·· ··
One tablet three times a day 62 (20%) 65 (22%) ·· ··
Two tablets twice a day 35 (12%) 32 (11%) ·· ··
Mode of onset of labour
Spontaneous 33 (11%) 55 (18%) RR 0·59 (0·42 to 0·83) 0·0025
Induced or pre-labour rupture of membranes and 
stimulation
215 (71%) 200 (67%) RR 1·06 (0·95 to 1·17) 0·30
Pre-labour caesarean 56 (18%) 44 (15%) ·· ··
Initiation of delivery‡
Severe maternal symptoms, n/N (%) 17/271 (6%) 28/244 (11%) ·· ··
Maternal serum bile acid, n/N (%) 53/271 (20%) 32/244 (13%) ·· ··
Fetal compromise, n/N (%) 24/271 (9%) 24/244 (10%) ·· ··
Gestational age, n/N (%) 161/271 (59%) 150/244 (61%) ·· ··
Maternal request, n/N (%) 32/271 (12%) 29/244 (12%) ·· ··
Other§, n/N (%) 37/271 (14%) 33/244 (14%) ·· ··
Estimated blood loss at delivery, mL 350 (250 to 600) 400 (250 to 600) Median difference –50 (–95 to –5) 0·029
<500 195 (64%) 185 (62%) ·· ··
≥500 and <1000 79 (26%) 80 (27%) ·· ··
≥1000 30 (10%) 34 (11%) ·· ··
Data are mean (SD), median (IQR), or n (%), unless otherwise indicated; N is equal to the total number of infants in the group unless otherwise indicated; <1% of observations 
are missing, unless indicated. RR=risk ratio. *N represents the number of women with data before randomisation, and at least one measurement post-randomisation, 
included in the model. †Between randomisation and delivery, adjusted for baseline measures. ‡Indications are not mutually exclusive (might be more than one indication per 
participant). §Reasons included pre-eclampsia and reduced fetal movement.
Table 3: Maternal outcomes
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differences were found between groups in the number of 
nights spent in the neonatal unit or the main diagnosis 
for neonatal unit admission (not formally tested). Other 
perinatal secondary outcomes are shown in table 2 and 
the appendix (pp 29–30).
Post-randomisation maternal itch score was lower in 
the ursodeoxycholic acid group than in the placebo group 
(mean difference –5·7 mm [95% CI –9·7 to –1·7], 
p=0·0054; table 3, figure 2, appendix p 31). Bile acid 
and alanine transaminase concentrations reduced over 
time after randomisation in both groups; however, the 
reduction in bile acid concentration was smaller in the 
ursodeoxycholic acid group compared with the placebo 
group (adjusted geometric mean ratio 1·18 [95% CI 
1·02 to 1·36], p=0·030). By contrast, a reduction in 
alanine transaminase concentration was found in the 
ursodeoxycholic acid group compared with the placebo 
group (adjusted geometric mean ratio 0·74 (0·66 to 0·83), 
p<0·0001). Median estimated blood loss was in the 
normal range for both groups, but was lower in women 
taking ursodeoxycholic acid than those taking placebo 
(median difference 50 mL [95% CI –95 to –5]). Other 
maternal secondary outcomes are shown in table 3 and 
the appendix (p 32).
Figure 2: Changes in maternal itch score (A, B), bile acid concentration (C, D), and alanine transaminase concentration (E, F) over 10 weeks post-randomisation
Data are actual mean (95% CI) or estimated mean (95% CI). Estimated means are adjusted for baseline measures and minimisation factors.
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Eight serious adverse events were reported, six of 
which were in the placebo group. None of the serious 
adverse events were considered to be related to the trial 
intervention (table 4, appendix p 33). 72 adverse events 
were reported: 31 in the ursodeoxycholic acid group and 
41 in the placebo group. Of note, the same number of 
patients in each group (n=10) reported adverse events 
related to gastrointestinal disorders.
Around two thirds of women in both groups (203 [67%] 
of 304 in the ursodeoxycholic acid group and 198 [66%] of 
300 in the placebo group) took a maximum of one tablet 
twice a day (equivalent to 1000 mg ursodeoxycholic acid 
in the ursodeoxycholic acid group). Similar numbers of 
women in both groups discontinued the intervention: 
24 (8%) of 304 in the ursodeoxycholic acid group and 
29 (10%) of 300 in the placebo group, with similar 
numbers of discontinuations in both groups instigated 
by clinicians and participants (table 4). In a planned 
sensitivity analysis, excluding infants whose mothers 
took less than 90% of the trial medication, a similar 
proportion of infants had the primary outcome 
of perinatal death, preterm delivery, or neonatal unit 
admission for at least 4 h (appendix p 34): 49 (23%) of 
217 infants in the ursodeoxycholic acid group compared 
with 44 (23%) of 190 infants in the placebo group 
(adjusted RR 0·91 [95% CI 0·63–1·32], p=0·63).
In planned subgroup analyses (figure 3, appendix p 35), 
we found no significant interaction of highest bile 
acid concentration before randomisation (<40 µmol/L, 
≥40 µmol/L), gestational age at randomisation (<34 weeks’ 
gestation, ≥34 weeks’ gestation), or pregnancy (singleton, 
twin) with the incidence of the primary outcome, the 
primary outcome components, itch score, or bile acid 
concentration post-randomisation.
In requested post-hoc exploratory analyses, the 
proportion of infants with the primary outcome, whose 
mothers had a highest bile acid concentration of at least 
100 µmol/L at randomisation, was similar in the two 
groups: nine (39%) of 23 infants in the ursodeoxycholic 
acid group compared with seven (41%) of 17 in the placebo 
group (appendix p 32). No difference was found in the 
proportion of women with spontaneous or iatrogenic 
preterm birth between the groups (appendix p 36).
We found no significant difference in total cost 
(maternal costs, infant costs, and cost of ursodeoxycholic 
acid) between the two trial groups: mean £5420 (SE 284) 
in the ursodeoxycholic acid group versus mean £5892 
(SE 353) in the placebo group (adjusted difference –£429 
[95% CI –1235 to 377], adjusted p=0·30; appendix p 37).
Discussion
In this trial of women with intrahepatic cholestasis of 
pregnancy, ursodeoxycholic acid was not effective in 
reducing a composite of adverse perinatal outcomes. 
Although ursodeoxycholic acid appeared to be safe, it 
had no clinically meaningful effect on maternal 
itch symptoms. It did not reduce maternal bile acid 
concentrations, and the reduction in alanine transaminase 
was of uncertain clinical significance, given that alanine 
transaminase is not known to be associated with the risk 
of stillbirth or preterm labour in intrahepatic cholestasis 
of pregnancy.1 The analysis in women who reported 
adherence to the intervention reduced the effect size for 
the primary outcome, and subgroup analyses did not 
identify any subgroup that showed a greater response to 
ursodeoxycholic acid. A 2019 meta-analysis1 identified that 
the risk of stillbirth increases in women with intrahepatic 
cholestasis of pregnancy with peak bile acid concentrations 
of at least 100 µmol/L, and that the risk of preterm birth 
increases with peak bile acid concentrations of at least 
Ursodeoxycholic 
acid (n=304)
Placebo 
(n=300)
Serious adverse events* 2 6
System organ class of serious adverse events
Congenital, familial, and genetic disorders 0 1
Hepatobiliary disorders 0 1
Infections and infestations 1 1
Metabolism and nutrition disorders 0 1
Pregnancy, puerperium, and perinatal conditions 1 1
Reproductive system and breast disorders 0 1
Adverse events 31 41
Not related to study intervention 15 31
Possibly related to study intervention 8 9
Probably related to study intervention 1 0
Missing data 7 1
System organ class of adverse events
Blood and lymphatic system disorders 4 4
Gastrointestinal disorders 10 10
Pregnancy, puerperium, and perinatal conditions 7 18
Other 10 9
Discontinued intervention 24/304 (8%) 29/300 (10%)
Clinician decision 10/24 (42%) 10/29 (34%)
Consultant wanted participant to receive ursodeoxycholic acid 3/10 (30%) 2/10 (20%)
Increased bile acids or alanine transaminase, or itch, or both 6/10 (60%) 8/10 (80%)
Nausea, vomiting, or upset stomach 1/10 (10%) 0
Participant decision 16/24 (67%) 22/29 (76%)
Itch improved or manageable without medication 1/13 (8%) 1/19 (5%)
Did not want medication or did not collect medication 5/13 (39%) 4/19 (21%)
Increased bile acids or alanine transaminase, or itch, or both 6/13 (46%) 8/19 (42%)
Nausea, vomiting, or upset stomach 1/13 (8%) 2/19 (11%)
Stopped trial drug for a week 0 1/19 (5%)
Wanted ursodeoxycholic acid 0 3/19 (16%)
Not known 3 3
Action after discontinuation
Prescribed ursodeoxycholic acid 17/23 (74%) 21/27 (78%)
Not prescribed ursodeoxycholic acid 6/23 (26%) 6/27 (22%)
Not known 1 2
Data are number of events or n/N (%). Adverse events and serious adverse events were classified according to system 
organ class terminology.20 *None of the serious adverse events were related to the study intervention.
Table 4: Adverse events and medication discontinuation
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40 µmol/L. In subgroups of women identified by higher 
peak bile acid concentration at study enrolment in our 
study, there was no discernible effect of ursodeoxycholic 
acid on the primary perinatal composite outcome, its 
components, or key maternal outcomes. A biologically 
plausible and clinically important reduction is unlikely to 
have been missed. We have previously reported that 
clinicians and patients considered at least a 30 mm 
(95% CI 15–50) improvement in itch score (from a 
baseline score of 60 mm) to be a clinically important 
difference;10 therefore, the 5 mm reduction in itch score 
reported in this trial is unlikely to be clinically useful. 
Although some secondary outcomes appear to be 
significantly different (at 95% CIs), the effects do not 
support a unified action related to ursodeoxycholic acid.
To evaluate real-world effectiveness of the intervention, 
the trial included pregnant women presenting with 
pruritus and abnormal maternal bile acid concentrations, 
which are the criteria commonly used to identify women 
with intrahepatic cholestasis of pregnancy. Clinicians 
would be likely to offer ursodeoxycholic acid to these 
women in the absence of other diagnoses. The study 
population had a similar range of elevated bile acid 
concentrations to other multicentre cohorts,21 with around 
three-quarters of women with bile acid concentrations of 
lower than 40 µmol/L.
A strength of this study was its size, which was 
considerably larger than any previous trial identified in the 
literature. The trial was rigorously conducted to a 
prespecified protocol without changes. The study was done 
in 33 maternity units in England and Wales, and it included 
women who were representative of the wider population of 
pregnant women in terms of demographics and spectrum 
of disease. Recruitment reached the target number of 
participants within the prespecified time period, indicating 
equipoise and a willingness to participate from clinicians 
and pregnant women.
A limitation of this study was that the incidence of the 
primary outcome in the control group was lower than 
that estimated for the sample size calculation. At the 
time of trial inception, we used the best available data 
(from the PITCH pilot study,10 which had a similar 
population of women with intrahepatic cholestasis 
of pregnancy, and the Cochrane systematic review 
in this field9) to estimate the incidence of perinatal 
death, preterm birth, and neonatal unit admission. 
In our subsequent individual patient data analysis,1 we 
reported that 412 (13%) of 3080 women with intrahepatic 
cholestasis of pregnancy had spontaneous preterm birth, 
which was a much lower incidence than that reported 
in the Cochrane systematic review (39 [44%] of 89), 
highlighting the limitations of using small samples to 
estimate our primary event rate for sample size 
calculation. The trial primary outcome event rate was 
reviewed by the Data Monitoring Committee, but 
because the event rate was similar in the two groups, 
extending the trial was not considered to be necessary. 
Although the trial could theoretically have insufficient 
power to show a difference between groups, the con-
sistent absence of effect in both the analysis of women 
who adhered to the intervention, and in subgroup 
analyses of women at greatest risk of adverse perinatal 
outcomes (bile acid concentration ≥40 µmol/L at 
enrolment), suggest that this is unlikely.
In contrast to previous meta-analyses,8,9 we did not 
find that ursodeoxycholic acid reduced maternal bile 
acid concentrations. Enzymic assays used to quantify 
total serum bile acids detect synthetic ursodeoxycholic 
acid as well as cholic acid and chenodeoxycholic acid, 
the pathologically elevated bile acids in intrahepatic 
cholestasis of pregnancy that are implicated in the 
pathogenesis of fetal complications.22 Treatment with 
ursodeoxycholic acid reduces the proportion of cholic 
acid and chenodeoxycholic acid,22 but it might be 
Figure 3: Subgroup analyses for the primary outcome and its main components
UDCA=ursodeoxycholic acid. RR=risk ratio.
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associated with an increase in total bile acid concentration, 
because of elevated serum concentrations of the drug. 
Therefore, the interpretation of bile acid concentrations 
in clinical practice and in this trial is complex. Because 
we found that bile acid concentrations were reduced even 
in the placebo group, some women who were initially 
diagnosed with intrahepatic cholestasis of pregnancy 
might have had a different disease, with transient raised 
maternal bile acid concentrations and a different 
underlying pathophysiology. Other trials in intrahepatic 
cholestasis of pregnancy have reported a similar 
reduction in bile acid10,23 or alanine transaminase24 
concentrations in the placebo group. These results 
highlight that placebo groups might provide the most 
unbiased assessment of the natural history of a condition, 
avoiding the selection bias that might occur during 
enrolment into case series, particularly in treated women.
We considered possible sources of bias for this trial. 
Selection bias was unlikely because of the randomisation 
process, including robust allocation-sequence conceal-
ment. Performance bias was reduced by effective masking 
of the intervention to clinicians, patients, and data 
collectors, such that identification of the active treatment 
was minimal, with the two groups receiving the same 
antenatal and intrapartum care pathways. Assessment of 
the outcome was also masked, minimising detection bias. 
Differences in attrition between the groups were small, 
with similar numbers discontinuing the intervention. 
We aimed to avoid reporting bias by presenting 
all prespecified secondary outcomes, including the 
secondary analyses for which effect size measures were 
calculated, and interpreting secondary outcomes with 
caution to avoid over interpretation.
The trial results support the findings of the pilot 
study,10 which reported only a small reduction in 
maternal itch symptoms, less than that judged by 
women and health-care professionals to be clinically 
useful. We have updated the Cochrane systematic 
review, including data from this trial and four others for 
stillbirth as an outcome,10,24–26 two additional trials for 
spontaneous preterm birth24,25 and total preterm birth,10,23 
and one additional trial for neonatal unit admission.10 
We confirmed that the pooled results do not show a 
significant difference in most adverse perinatal 
outcomes between treatment with ursodeoxycholic acid 
and placebo. Our meta-analysis showed a significant 
reduction in total preterm birth, but not spontaneous 
preterm birth, with ursodeoxycholic acid, probably 
reflecting a difference in iatrogenic deliveries. In the 
absence of any discernible effect of ursodeoxycholic 
acid on iatrogenic preterm birth in women with peak 
bile acid concentrations at enrolment of more than 
40 µmol/L, or in those presenting before 34 weeks’ 
gestation, a strong biological effect of ursodeoxycholic 
acid seems unlikely.
Ursodeoxycholic acid is the only treatment consistently 
proposed in guidelines as a disease-modifying drug; no 
other treatments are widely used for prevention of the 
adverse perinatal outcomes associated with intrahepatic 
cholestasis of pregnancy, although a study is planned to 
evaluate the use of rifampicin.27 Our individual patient 
data analysis1 suggests that in women with peak bile acid 
concentrations lower than 100 µmol/L, the risk of 
stillbirth is similar to that of the general pregnant 
population, whereas the risk is significantly higher in 
women with peak bile acid concentrations of at least 
100 µmol/L at any time in the pregnancy. Coexisting 
pregnancy complications, such as pre-eclampsia or 
gestational diabetes, might increase the risk of stillbirth.28 
The only intervention to affect adverse perinatal 
outcomes is likely to be appropriately planned delivery.
Some subgroups of women with intrahepatic chole-
stasis of pregnancy, which have not yet been identified, 
could respond to ursodeoxycholic acid (eg, those with or 
without comorbidities), either by reduction of maternal 
symptoms or reduction of adverse perinatal outcomes. 
For instance, abnormally high bile acid concentrations are 
associated with stillbirth in intrahepatic cholestasis of 
pregnancy,1 and in-vitro studies have shown that 
ursodeoxycholic acid might be protective against bile-acid 
induced cardiac arrhythmias,29 potentially mediated 
through reduction of specific bile acid species.22 However, 
further understanding of the pathophysiology under-
pinning stillbirth (and therefore the target for intervention) 
is needed. Additional work is also needed to confirm the 
likely pruritogen in intrahepatic cholestasis of pregnancy 
to identify a target for therapeutic treatments; progesterone 
sulfates30 and lysophosphatidic acid31 have been proposed 
as candidates. However, the lack of in-vivo evidence 
of benefit should preclude further routine clinical use 
of ursodeoxycholic acid, even in the absence of harm, to 
avoid women being offered an unproven treatment.
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